Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline
Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan’s Best-in-Class Medical Aesthetics Portfolio and Pipeline DUBLIN, IRELAND and NEWPORT BEACH, CA – SEPTEMBER 14, 2018 - Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the